Fujifilm expands C&G therapy options with acquisition of recombinant protein maker
Fujifilm is expanding its footprint within the US yet again, this time with another East Coast acquisition within driving distance of its new $2 billion headquarters.
Fujifilm Irvine Scientific has acquired recombinant protein maker Shenandoah Biotechnology. The Pennsylvania manufacturer makes cytokines and growth factors and recently launched a CTG grade line that was made in its new facility. This acquisition will allow Fujifilm to easily transition between preclinical and clinical phases of trials.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.